On September 17, Halozyme (NASDAQ:HALO) priced $1.3 billion of convertible senior notes due 2033, an offering that grew from an originally planned $1.05 billion as demand came in. The notes carry a 1.50% coupon and convert into stock at $139.84 a share, a 27.5% premium to the $109.68 closing price that day. Investors who like a growth story now have to decide how much a bigger balance sheet changes the math. The timing matters, because Halozyme just posted one of its strongest quarters yet and raised its full-year outlook again.
The Royalty Engine Keeps Revving
Second-quarter revenue hit $481.0 million, up 48% from $325.7 million a year earlier, and royalty revenue climbed 50% to $307.7 million. That growth leaned heavily on ENHANZE partner products already on the market, including VYVGART Hytrulo from argenx and DARZALEX SC from Janssen, which points to a business collecting on drugs that already cleared regulators rather than betting on ones that haven’t. Operating income rose to $287.7 million from $202.4 million, and non-GAAP diluted earnings per share grew to $2.28 from $1.54, so the growth reached the bottom line instead of getting absorbed by expenses.
Management responded by raising full-year guidance across the board, now calling for adjusted EBITDA of $1.225 billion to $1.280 billion, up 86% to 95% over 2025. Halozyme also signed five new ENHANZE and Hypercon collaboration agreements through July, including deals with Vertex, Oruka, GSK and Incyte, beating its own goal of three for the year and spreading the royalty base into oncology, immunology and, for the first time, a nucleic acid therapeutic. On top of that, the company bought back 4.8 million shares for $332.8 million in the second quarter alone under a $1.0 billion repurchase program that runs through 2028.
The Fine Print On That Debt
A $1.3 billion note sale is still $1.3 billion of new senior obligations, and the interest rate isn’t the only cost. If the stock ever trades above $139.84, conversion starts diluting shareholders, and that dilution protection only goes so far: the capped call transactions Halozyme layered on top max out at $208.39 a share, a 90% premium to the September 17 price. Above that level, holders get diluted with no offset. The company is using part of the proceeds to retire $151.7 million of its 2027 notes and $220.0 million of its 2028 notes, at a combined repurchase cost near $652.5 million, which pushes the debt further out but doesn’t erase it.
Meanwhile, the cost side of the business is creeping up. Cost of sales rose to $79.2 million from $46.4 million on higher bulk rHuPH20 sales, and selling, general and administrative expense jumped to $57.0 million from $41.6 million, partly on patent infringement litigation costs. Research and development spending nearly doubled to $27.7 million as the company folds in its Elektrofi and Surf Bio acquisitions. None of that is alarming on its own, but it’s a reminder that growth here isn’t costless.
What The Smart Money Sees
Hedge fund ownership climbed from 32 funds to 38 last quarter, a sign of accumulating rather than fading interest. Yet the stock trades at a forward P/E of just 11.47, as of September 21, a modest multiple for a company guiding to adjusted EBITDA growth near 90%. Short interest sits at 17.19% of float, which is high enough to suggest a real bear camp rather than routine hedging. That combination points to a genuine disagreement about what happens next.
Two Stories, One Stock
Halozyme heads into this note sale with a business that’s growing faster than its valuation implies, backed by a diversifying royalty stream and a management team willing to keep buying back stock. But it also now carries a bigger debt load with a dilution ceiling set at $208.39, and expenses are rising alongside revenue. For the bulls, the case rests on royalty growth continuing to outrun the new interest expense. For the bears, it rests on the stock testing that conversion math sooner than the capped calls can fully absorb.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
